C4 Can pharmacovigilance shed light on adherence?

Thursday 1 September 2016
14:30-17:30
Hilton Buenos Aires : Atlantico C, 3 hours

Organised by the FIP Social and Administrative Pharmacy Section and the FIP Industrial Pharmacy Section

Simultaneous translation in Spanish


Introduction

  Pharmacovigilance has traditionally focused on identifying and evaluating previously unknown adverse reactions to medicines through centralised systems for collecting reports of suspected adverse drug events. Today, the aims of pharmacovigilance are wider: to enhance patient care and patient safety in relation to medication. Further, pharmacovigilance systems increasingly recognise medication errors, commonly defined as unintentional errors in the prescribing, dispensing, administration or monitoring of a medicine while under the control of a health care professional, patient or consumer. As errors in administration by patients are considered part of pharmacovigilance, patient non-adherence could be part of pharmacovigilance. In this interactive session, participants will elaborate whether and how patient adherence could be considered in pharmacovigilance and how pharmacists in various practice settings could contribute.

 

Learning objectives

At the conclusion of this knowledge-based session, participants will be able to:

  1. Describe the current scope of pharmacovigilance and how it relates to patient adherence
  2. Define how patient adherence could be considered in pharmacovigilance
  3. Identify opportunities for pharmacists in various practice settings to contribute towards improving patient adherence as part of pharmacovigilance. 

Chairs

Katja Hakkarainen (EPID Research, Sweden) and Ulf Janzon (MSD, Sweden) 

Programme

14:30

1)      Introduction

14:35

2)      Pharmacovigilance today – How does patient adherence fit in? 

Sten Olsson (WHO Programme Uppsala Monitoring Centre, Sweden)

15:05

3)      Pharmacovigilance and adherence experts’ visions on considering patient adherence in pharmacovigilance

a)      Pharmacovigilance in Brazil

Fernando Pereira (MSD, Brazil) 

b)      Expanding the scope of pharmacovigilance towards including adherence

Delese Mimi Darko (Food and Drugs Authority, Ghana)

c)       Novel strategies for detecting information on adherence to medication regimens

Marie-Paule Schneider (Policlinique Médicale Universitaire de Lausanne, Switzerland)

15:50 – 16:10 Coffee/tea break

16:10

4)      Workshop: How could pharmacists contribute to improving patient adherence as part of pharmacovigilance?

 17:10

5)      Plenary discussion and summary